Latest from Perlmutter Cancer Center at NYU Langone

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma. 
 
Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.
Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma. 
 
Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.
Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.
Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma. 
Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology. 
Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.
Publication Bottom Border
Border Publication
x